Abstract Details

Title Data-driven phenotypic clustering of Parkinson’s disease patients seeking deep brain stimulation

Topic Movement Disorders

Presentation(s) P6 - Poster Session 6 (5:30 PM-6:30 PM)

Poster/Presentation
Number 5-008

Objective

To identify unique phenotypic clusters amongst participants in RAD-PD (Registry for the Advancement of Deep Brain Stimulation in Parkinson’s Disease).

Background RAD-PD is a longitudinal quality improvement registry that systematically characterizes participants through patient reported outcome measures and clinician administered scales, with the overarching goal of improving outcomes from deep brain stimulation (DBS) in PD. Multiple investigations demonstrate that DBS improves motor function and quality of life (QoL). Less is understood about non-motor outcomes and determinants.

Design/Methods A variety of demographic/social, disease-related, motor, non-motor, quality of life, and treatment-related datapoints are captured in RAD-PD. Continuous data variables from participants with complete pre-operative assessments were analyzed using R software. A pairs plot correlation analysis, principal component analysis (PCA) and hierarchical clustering analysis (HCA) with normalized data were conducted.

Results Data from 133 subjects were included. Amongst 32 categories of RAD-PD data covering demographic/disease (n=5), non-motor (n=18), motor (n=3), cognitive (n=3) and QoL (n=3) variables, all 3 QoL scale scores were strongly correlated with each other (r=0.47-0.64, p<0.0001), and were otherwise most highly correlated (r>0.4) with measures of depression, anxiety, sleep/fatigue, NMSS total, mood/cognition, IADLs, and MDS-UPDRS part 2. Motor and disease-related variables did not strongly correlate with other variables. PCA revealed two dimensions that together explain 38.7% of the variance in the data, driven mainly by quality of life, NMSS domain/total scores, and QUIP-RS subscores/total scores. HCA classified individuals into two groups that were differentiated based on non-motor (NMSS and ICD scores), cognitive, and QoL features.

Conclusions

While recommendations for DBS in PD are often driven by motor disease features, QoL and non-motor symptoms are prominent features that are closely related and can be combined to classify phenotypic clusters. Such data-driven classifications can be used in the RAD-PD cohort for novel outcomes analyses and predictive modeling.

Authors/Disclosures
Joohi Jimenez Shahed, MD, FAAN (Icahn School of Medicine at Mount Sinai) PRESENTER	Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medtronic. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Jimenez Shahed has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BlueRock. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Treefrog. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for RebrAIn. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BlueRock Therapeutics. Dr. Jimenez Shahed has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PhotoPharmics. Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Emalex. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. The institution of Dr. Jimenez Shahed has received research support from Amneal. The institution of Dr. Jimenez Shahed has received research support from Annovis. The institution of Dr. Jimenez Shahed has received research support from SAGE. The institution of Dr. Jimenez Shahed has received research support from Ono Pharmaceuticals. The institution of Dr. Jimenez Shahed has received research support from BlueRock. The institution of Dr. Jimenez Shahed has received research support from Neuron23. Dr. Jimenez Shahed has received personal compensation in the range of $0-$499 for serving as a Faculty with Movement Disorders Society. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Faculty with ��ɫ��. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with Parkinson Foundation.
	No disclosure on file
Michele K. York, PhD, ABPP-CN (Baylor College of Medicine)	Dr. York has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for RAD-PD. The institution of Dr. York has received research support from Michael J. Fox Foundation. The institution of Dr. York has received research support from NIH. The institution of Dr. York has received research support from Takeda.
	No disclosure on file
	No disclosure on file
Mustafa S. Siddiqui, MD, FAAN	Dr. Siddiqui has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Boston Scientific Neuromodulation. Dr. Siddiqui has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. The institution of Dr. Siddiqui has received research support from Boston Scientific Neuromodulation. The institution of Dr. Siddiqui has received research support from Abbvie. The institution of Dr. Siddiqui has received research support from National Institute of Health .
	No disclosure on file

��ɫ����

��ɫ����

��ɫ��

��ɫ��